Product Information for the Patient
Tivicay 10mg Film-Coated Tablets
Tivicay 25mg Film-Coated Tablets
Tivicay 50mg Film-Coated Tablets
dolutegravir
Read this entire product information carefully before starting to take this medicine(or your child, if the patient), because it contains important information for you.
-This medicine has been prescribed only for you(or your child, if the patient), and should not be given to other people even if they have the same symptoms as you, as it may harm them.
1.What isTivicayand for what it is used
2.What you need to knowbefore starting to takeTivicay
3.How to takeTivicay
4.Possible adverse effects
6.Contents of the package and additional information
Tivicay contains dolutegravir as its active ingredient. Dolutegravir belongs to a group of antiretroviral medications calledintegrase inhibitors (INIs).
Tivicay is used to treathuman immunodeficiency virus (HIV) infection(HIV) in adults, adolescents, and children at least 6 years old and weighing at least 14 kg.
Tivicay does not cure HIV infection; it reduces the amount of virus in the body and keeps it at a low level. As a result, it also increases the number of CD4 cells in the blood. CD4 cells are a type of white blood cell that are important for helping the body fight off infections.
Not everyone responds to Tivicay treatment in the same way. Your doctor will monitor the effectiveness of your treatment.
Tivicay is always used in combination with other antiretroviral medications (combination therapy). To control your HIV infection and to prevent your condition from worsening, you must continue taking all your medications, unless your doctor has instructed you to stop taking one of them.
Do not take Tivicay:
Warnings and precautions
Be aware of important symptoms
Some people taking medications for HIV infection develop other disorders, which can be serious. These include:
You need to know what important signs and symptoms to be aware of while taking Tivicay.
Children
Do not give this medication to children under 6 years of age, weighing less than 14 kg, or with HIV infection resistant to other similar medications to Tivicay. The use of Tivicay film-coated tablets in children under 6 years of age or weighing less than 14 kg has not yet been studied.
Children mustattend scheduled medical appointments(see “Use in children and adolescents” in section 3 for more information).
Other medications and Tivicay
Inform your doctor if you (or your child, if the patient) are taking, have taken recently, or may need to take any other medication.
Do not take Tivicay with the following medication:
Some medications may affect the functioning of Tivicay, orincrease the likelihood of adverse effects. Tivicay may also affect the functioning of some other medications.
Inform your doctorif you (or your child) are taking any of the following medications:
Pregnancy
If you are pregnant,think you may be pregnantor intend to become pregnant:
_Consult your doctorabout the risks and benefits of takingTivicay
Inform your doctor immediately if you become pregnant or intend to become pregnant. Your doctor will review your treatment. Do not interrupt treatment with Tivicay without consulting your doctor, as this could harm you and your fetus.
Breastfeeding
A small amountofthe components of Tivicay may pass into breast milk.
If you are breastfeeding or plan to breastfeed,you must consult your doctor as soon as possible.
Driving and operating machinery
Tivicay may make you feel dizzy and have other adverse effectsthat reduce your attention.
Tivicay contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Your doctor will decide what is the correct dose of Tivicay for you.
Swallow the/ the tablets with a little liquid.
Tivicay can be takenwith or without food. When taking Tivicay twice a day, your doctor may advise you to take it with food.
Tivicay is also available indisintegrating tablets. Film-coated tablets and disintegrating tabletsare not the same, therefore, do not switch between film-coated tablets and disintegrating tablets without consulting your doctor first.
Use in childrenand adolescents
Antacids
Antacids, used to treatindigestionandheartburnofstomach, may interrupt the absorption of Tivicay in your body and make it less effective.
Do not take an antacidwithin 6 hours before taking Tivicay, or at least 2 hours after taking it. Other medications that reduce acidity, such as ranitidine and omeprazole, can be taken at the same time as Tivicay.
Supplements or multivitamin preparations containing calcium, iron, or magnesium
Supplements or multivitamin preparations containing calcium, iron, or magnesium may interrupt the absorption of Tivicay in your body and make it less effective.
If you take Tivicay with food, you can take supplements or multivitamin preparations containing calcium, iron, or magnesium at the same time as Tivicay.If you do not take Tivicay with food, do not take a supplement or multivitamin preparation containing calcium, iron, or magnesiumwithin 6 hours before taking Tivicay, or at least 2 hours after taking it.
If you take more Tivicay than you should
If you (or your child) exceed the number of Tivicay tablets,contact your doctor or pharmacist for advice. If possible, show them the Tivicay box.
If you forget to take Tivicay
If you (or your child) forget a dose, take it as soon as you remember. But if there are less than 4 hours until your next dose, skip the dose you forgot and take the next one at the usual time. Then continue your treatment as before.
Do not interrupt Tivicay treatment
Take Tivicay until your doctor tells you to. Do not stop taking it unless your doctor advises you to.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Allergic reactions
These are rare in people taking Tivicay. The signs include:
Very common side effects
Thesecan affectmore than 1 in 10people:
Common side effects
Thesecan affectup to 1 in 10people:
Uncommon side effects
These may affectup to 1 in 100 people:
Rare side effects
Thesecan affectup to 1 in 1,000 people:
Symptoms of infection and inflammation
People with advanced HIV infection (AIDS) have a weakened immune system and are more likely to develop serious infections (opportunistic infections). These infections may have developed "silently", not being detected by the weakened immune system before treatment began. After starting treatment, the immune system becomes stronger and can fight these infections,which can cause symptoms of infection or inflammation. The symptoms usually includefever, as well as some of the following:
In rare cases, as the immune system becomes stronger, it may also attack healthy tissues (autoimmune disorders). The symptoms of autoimmune disorders may appear many monthsafterstarting to take medicines to treat HIV infection. The symptoms may include:
If you (or your child) experience any symptoms of infection and inflammationor if you notice any of the above symptoms:
Joint pain, stiffness and bone problems
Some people taking combined HIV treatment developosteonecrosis. In this condition, parts of the bone tissue die due to reduced blood supply to the bones. People may be more prone to this condition:
The signs of osteonecrosis include:
If you notice any of these symptoms:
Effects on weight, lipids and blood glucose
During HIV treatment, there may be an increase in weight and levels of lipids and blood glucose. This is partly related to recovery of health and lifestyle, and sometimes to the HIV medicines themselves. Your doctor will evaluate these changes.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, evenif it ispossibleside effects that do not appear in this leaflet. You can also report them directly through the national notification system included in theAppendixV. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and bottle after CAD.
Tivicay 10mg film-coated tablets
Store in the original packaging to protect it from moisture. Keep the bottle tightly closed. Do not discard the desiccant. Do not ingest the desiccant.This medication does not require any special storage temperature.
Tivicay 25mg and 50mg film-coated tablets
This medication does not require special storage conditions.
Medications should not be disposed of through drains or trash.Ask your pharmacist how to dispose ofthe packaging and medications that you no longerneed.This will help protect the environment.
Composition of Tivicay
Appearance of the product and contents of the pack
The film-coated tablets of Tivicay 10mg are white, round, biconvex, engraved with “SV572”on one side and “10” on the other. The bottle contains a desiccant to reduce humidity. Once opened, keep the desiccant in the bottle, do not discard.
The film-coated tablets of Tivicay 25mg are pale yellow, round, biconvex, engraved with “SV572”on one side and “25” on the other.
The film-coated tablets of Tivicay 50mg are yellow, round, biconvex, engraved with “SV572”on one side and “50”on the other.
The film-coated tablets are supplied inbottles containing 30 or 90 tablets.Only some pack sizes may be marketed.
Marketing Authorization Holder
ViiV Healthcare BV
Van Asch van Wijckstraat 55H
3811 LP Amersfoort
Netherlands
Responsible for manufacturing
Glaxo Wellcome, S.A., Avda. Extremadura 3, 09400 Aranda de Duero, Burgos, Spain
or
Delpharm Poznan Spólka Akcyjna, Grunwaldzka 189, 60-322 Poznan, Poland.
For more information about this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien ViiV Healthcare srl/bv Tél/Tel:+ 32 (0) 10 85 65 00 | Lietuva ViiV Healthcare BV Tel: + 370 80000334 |
Luxembourg/Luxemburg ViiV Healthcare srl/bv Belgique/Belgien Tél/Tel:+ 32 (0) 10 85 65 00 |
Ceská republika GlaxoSmithKline, s.r.o. Tel: + 420 222 001 111 | Magyarország ViiV Healthcare BV Tel.: + 36 80088309 |
Danmark GlaxoSmithKline Pharma A/S Tlf.: + 45 36 35 91 00 | Malta ViiV Healthcare BV Tel: + 356 80065004 |
Deutschland ViiV Healthcare GmbH Tel.:+ 49 (0)89203 0038-10 | Nederland ViiV Healthcare BV Tel: + 31 (0)332081199 |
Eesti ViiV Healthcare BV Tel: + 3728002640 | Norge GlaxoSmithKline AS Tlf:+ 47 22 70 20 00 |
Ελλ?δα GlaxoSmithKlineΜονοπρ?σωπηA.E.B.E. Τηλ: + 30 210 68 82 100 | Österreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 |
España Laboratorios ViiV Healthcare, S.L. Tel: + 34 900 923 501 | Polska GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9000 |
France ViiV Healthcare SAS Tél.: + 33 (0)1 39 1769 69 | Portugal VIIVHIV HEALTHCARE, UNIPESSOAL, LDA Tel: + 351 21094 08 01 |
Hrvatska ViiV Healthcare BV Tel: + 385 800787089 | România ViiV Healthcare BV Tel: +40800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenija ViiV Healthcare BV Tel: + 386 80688869 |
Ísland Vistorhf. Sími: + 354 535 7000 | Slovenská republika ViiV Healthcare BV Tel: + 421 800500589 |
Italia ViiV Healthcare S.r.l Tel: + 39 (0)457741600 | Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 |
Κ?προς ViiV Healthcare BV Τηλ:+ 357 80070017 | Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 |
Latvija ViiV Healthcare BV Tel: + 37180205045 | United Kingdom(Northern Ireland) ViiV Healthcare BV Tel: + 44 (0)800 221441 |
Date of the last revision of this leaflet: {month} {year}.
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency:https://www.ema.europa.eu.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.